The results are in – 100s of market access execs told us about their predictions for and frustrations with the development of managed markets in the US.
Here’s a taster of some of the more surprising results:
- 48% said market access considerations still aren’t being considered till phase 2 of drug development
- The shift towards specialty medicines no longer seems to be seen as a challenge
- But clarity from payers is still the Holy Grail for market access execs
Download the results in full on the right
I look forward to hearing your thoughts!